Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5938-5945

  Acosta, Edward P ^a   Limoli, Kay L ^b   Trinh, Lan ^b   Parkin, Neil T ^c   King, Jennifer R ^a   Weidler, Jodi M ^b   Ofotokun, Ighovwerha ^d   Petropoulos, Christos J ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b MONOGRAM BIOSCIENCES   (United States)

^c DATA FIRST CONSULTING INC   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; ETRAVIRINE; INDINAVIR; INTEGRASE INHIBITOR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; SAQUINAVIR; TIPRANAVIR;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EXPOSURE; HUMAN; IN VITRO STUDY; LINEAR REGRESSION ANALYSIS; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; SERUM PROTEIN BINDING CORRECTION FACTOR;

BIOLOGICAL ASSAY; BLOOD PROTEINS; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; PROTEIN BINDING; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84868007869     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00691-12     Document Type: Article

References (57)

1. Abbott Laboratories. 2010. Kaletra (lopinavir/ritonavir) tablets and oral solution: highlights of prescribing information. Abbott Laboratories, North Chicago, IL.
2. Abbott Laboratories. 2010. Norvir (ritonavir) tablets and oral solution: highlights of prescribing information. Abbott, North Chicago, IL.
3. Agouron. 2010. Viracept (nelfinavir mesylate) tablets and oral powder: prescribing information. Agouron, La Jolla, CA.
4. Ananworanich J, et al. 2005. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleosidepretreated children. Pediatr. Infect. Dis. J. 24:874-879.
5. Barrail-Tran A, et al. 2008. Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen. Antimicrob. Agents Chemother. 52: 1642-1646.
6. Boehringer-Ingelheim. 2010. Aptivus (tipranavir) tablets and oral solution: highlights of prescribing information. Boehringer-Ingelheim, Ridgefield, CT.
7. Boehringer-Ingelheim. 2010. Viramune (nevirapine) tablets and oral suspension: highlights of prescribing information. Boehringer-Ingelheim, Ridgefield, CT.
8. Bristol-Myers Squibb. 2010. Reyataz (atazanavir sulfate) capsules: highlights of prescribing information. Bristol-Myers Squibb, Princeton, NJ.
9. Bristol-Myers Squibb. 2010. Sustiva (efavirenz) capsules and tablets: highlights of prescribing information. Bristol-Myers Squibb, Princeton, NJ.
10. Clifford DB, et al. 2005. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann. Intern. Med. 143:714-721.
11. DeJesus E, et al. 2006. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J. Acquir. Immune Defic. Syndr. 43:1-5.
12. Demeter LM, et al. 2009. A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients. AIDS 23:357-368.
13. de Vries-Sluijs TE, et al. 2003. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin. Pharmacokinet. 42:599-605.
14. Drusano GL, et al. 2001. Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable. J. Infect. Dis. 183: 1126-1129.
15. Eron JJ, Jr, et al. 2009. Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy. Antimicrob. Agents Chemother. 53:2335-2341.
16. Fletcher CV, et al. 2000. Pharmacologic characteristics of indinavir, didanosine, and stavudineinhuman immunodeficiency virus-infected children receiving combination therapy. Antimicrob. Agents Chemother. 44: 1029-1034.
17. Genentech. 2010. Invirase (saquinavir mesylate) capsules and tablets: prescribing information. Genentech, South San Francisco, CA.
18. Gieschke R, Fotteler B, Buss N, Steimer JL. 1999. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Clin. Pharmacokinet. 37:75-86.
19. GlaxoSmithKline. 2010. Lexiva (fosamprenavir calcium) tablets and oral suspension: highlights of prescribing information. GlaxoSmithKline, Research Triangle Park, NC.
20. Gonzalez de Requena D, et al. 2005. Atazanavir Ctrough is associated with efficacy and safety at 24 weeks: definition of therapeutic range. abstr 60. Sixth Int. Workshop Clin. Pharmacol. HIV Ther., Quebec City, Canada, 28 to 30 April 2005.
21. Grub S, et al. 2002. Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection. Clin. Pharmacol. Ther. 71:122-130.
22. Haas DW, et al. 2004. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18: 2391-2400.
23. Harrigan PR, Miller MD, McKenna P, Brumme ZL, Larder BA. 2002. Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 46:1067-1072.
24. Harrigan PR, et al. 2001. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 15:1671-1677.
25. Hazuda D, Iwamoto M, Wenning L. 2009. Emerging pharmacology: inhibitors of human immunodeficiency virus integration. Annu. Rev. Pharmacol. Toxicol. 49:377-394.
26. Hickman D, et al. 2004. Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir. Antimicrob. Agents Chemother. 48:2911-2917.
27. Hoefnagel JG, Koopmans PP, Burger DM, Schuurman R, Galama JM. 2005. Role of the inhibitory quotient in HIV therapy. Antivir. Ther. 10: 879-892.
28. Hsu A, et al. 2001. Assessment of plasma protein binding of lopinavir LPV) and ritonavir (RTV) between in vitro and ex vivo experiments and between HIV-infected patients and HIV-negative healthy volunteers, abstr 753. Eighth Conf. Retrovir. Opportunistic Infect., Chicago, IL, 4 to 8 February 2001.
29. Israili ZH, Dayton PG. 2001. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab. Rev. 33:161-235.
30. Kredo T, Van der Walt JS, Siegfried N, Cohen K. 2009. Therapeutic drug monitoring of antiretrovirals for people with HIV. Cochrane Database Syst. Rev. 2009: CD007268. doi:10.1002/14651858.CD007268.pub2.
31. la Porte CJL, et al. 2006. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev. Antivir. Ther. 3:4-14.
32. Lillibridge JH, et al. 1998. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab. Dispos. 26:609-616.
33. Luber A, et al. 2009. Steady-state pharmacokinetics (PK) of fosamprenavir (FPV) and raltegravir (RAL) alone and combined with unboosted and ritonavir-boosted FPV, abstr A1-1297. Abstr.49th Intersci. Conf. Antimicrob. Agents Chemother.
34. Mallolas J, et al. 2007. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study. HIV Med. 8:226-233.
35. Marcelin AG, Flandre P, Peytavin G, Calvez V. 2005. Predictors of virologic response to ritonavir-boosted protease inhibitors. AIDS Rev. 7:225-232.
36. Marcelin AG, et al. 2003. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 47:594-600.
37. Marzolini C, et al. 2001. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15:71-75.
38. Merck. 2010. Crixivan (indinavir mesylate) capsules: prescribing information. Merck, Whitehouse Station, NJ.
39. Merck. 2010. Isentress (raltegravir) tablets: highlights of prescribing information. Merck, Whitehouse Station, NJ.
40. Molla A, et al. 1998. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 250:255-262.
41. Molto J, et al. 2008. Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 52:3928-3932.
42. Morello J, et al. 2009. Use of different inhibitory quotients to predict early virological response to tipranavir in antiretroviral-experienced human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 53:4153-4158.
43. Morse GD, Catanzaro LM, Acosta EP. 2006. Clinical pharmacodynamics of HIV-1 protease inhibitors: use ofinhibitory quotientstooptimise pharmacotherapy. Lancet Infect. Dis. 6:215-225.
44. Naeger L, Zheng J, Struble K. 2006. Virologic response to tipranavir based on plasma concentration and baseline resistance parameters, abstr 639a. Conf. Retrovir. Opportun. Infect., Denver, CO, 5 to 8 February 2006.
45. Panel on Antiretroviral Guidelines for Adults and Adolescents. 2011. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, Washington, DC. http://www.aidsinfo.nih.gov/ContentFiles/Adult-and-Adolescent-GL.pdf. Accessed 14 October 2011.
46. Parkin NT, et al. 2004. Natural variation of drug susceptibility in wildtype human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48:437-443.
47. Petropoulos CJ, et al. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928.
48. Preston SL, et al. 2003. In vitro-in vivo model for evaluating the antiviral activity of amprenavir in combination with ritonavir administered at 600 and 100 milligrams, respectively, every12 hours. Antimicrob. Agents Chemother. 47:3393-3399.
49. Ribaudo HJ, et al. 2006. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group study. Clin. Infect. Dis. 42:401-407.
50. Rizk ML, et al. 2012. Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients. Antimicrob. Agents Chemother. 56:3101-3106.
51. Sadler BM, Gillotin C, Lou Y, Stein DS. 2001. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob. Agents Chemother. 45:30-37.
52. Song I, et al. 2009. Pharmacokinetic (PK) and pharmacodynamic (PD) relationship of S/GSK1349572, a next generation integrase inhibitor (INI), in HIV-1 infected patients, abstr WEPEB250. Fifth IAS Conf. HIV Pathog., Treat. Prevent., Cape Town, South Africa, 19 to 22 July 2009.
53. Tibotec. 2009. Intelence (etravirine) tablets: full prescribing information. Tibotec, Raritan, NJ.
54. Tibotec. 2010. Prezista (darunavir) tablet, film coated for oral use: full prescribing information. Tibotec, Raritan, NJ.
55. Winston A, et al. 2005. The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment- experienced HIV-1-infected individuals. AIDS 19:1393-1399.
56. Winston A, Khoo S. 2008. Clinical application of the inhibitory quotient: is there a role in HIV protease inhibitor therapy? Curr. Opin. HIV AIDS 3:608-611.
57. Zhang KE, et al. 2001. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob. Agents Chemother. 45:1086-1093.